-
In patients with stable coronary artery disease (CAD), medical therapy is the mainstay of treatment. Percutaneous coronary intervention (PCI) guided by angiographic stenosis is more effective than medical therapy at reducing angina, but does not change the rate of death or myocardial infarction (MI).
-
Patients with chronic kidney disease or who have had renal replacement therapy have often been excluded from trials of anticoagulation in atrial fibrillation (AF). In this study, the authors analyzed data from hospitalized patients with nonvalvular AF in Denmark from 1997 through 2008. Patients with chronic kidney disease with and without renal replacement therapy were identified from a national registry.
-
-
In the setting of acute ST segment elevation myocardial infarction (STEMI), warfarin is indicated for atrial fibrillation, a large dyskinetic or aneurysmal area of the left ventricle, or mural thrombus.
-
Patients presenting to the emergency department (ED) with chest pain are often admitted to "rule out" myocardial infarction (MI). Many of the patients are subsequently found to have noncardiac causes of chest pain.
-
Some patients who experience stroke or transient ischemic attack (TIA) of unknown cause (i.e., cryptogenic) are subsequently found to have a patent foramen ovale (PFO).
-
The Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Study compared two doses of dabigatran, a direct thrombin inhibitor, with warfarin for the prevention of stroke and systemic emboli in patients with nonvalvular atrial fibrillation (AF).
-
Aspirin and cancer prevention; rivaroxaban for pulmonary embolism; new rhinosinusitis practice guidelines; and FDA actions.
-
This paper reports registry data from a large, single-center patient cohort with myotonic dystrophy type 1 (DM1). Between January 2000 and December 2009, 914 adult patients were included in the DM1 Heart Registry at the authors' institution.
-
Various risk schemes have been promulgated for assessing the risk of stroke and bleeding in patients with atrial fibrillation (AF). These investigators used the Swedish Atrial Fibrillation cohort study to investigate the comparative utility of four schemes that have been validated in AF cohorts: CHADS2, CHA2DS2-VASc, HAS-BLED, and HEMORR2HAGES.